心脏手术中使用因子八抑制剂旁路活性(FEIBA)的安全性:倾向性匹配分析
回顾性分析斯坦福医院2018年7月至2023年6月接受体外循环心脏手术的成人患者(n=3,335),将术后使用FEIBA止血者与未使用者按1:1倾向性匹配(每组352例)。结果显示低剂量FEIBA不增加血栓栓塞事件、ICU停留时间或死亡率,但较高剂量与急性肾衰竭和术后输血增加相关。
要点
- 低剂量FEIBA不增加血栓栓塞事件、ICU停留或死亡风险。
- FEIBA剂量>750 U与急性肾衰竭风险增加相关。
- FEIBA剂量501-750 U与红细胞和血小板输注增加相关。
核心结论
- 低剂量FEIBA不增加血栓栓塞事件、ICU停留时间或死亡率,但较高剂量与急性肾衰竭和术后输血增加相关。
研究设计与样本
- 回顾性队列研究,纳入2018年7月1日至2023年6月30日斯坦福医院接受体外循环心脏手术的成人患者(n=3,335),按1:1倾向性评分匹配FEIBA使用者与未使用者(每组352例,共704例)。
主要发现
- FEIBA平均剂量为7.3 ± 5.5 U/kg。
- 倾向性匹配多因素logistic回归模型中,血栓栓塞结局、ICU停留时间或死亡率的比值比无统计学显著差异。
- FEIBA剂量>750 U与急性肾衰竭风险增加相关(OR 4.14;95% CI 1.61至10.36;P < 0.001)。
- 多因素线性回归显示FEIBA组术后血浆和冷沉淀输注更多。
- 仅501-750 U剂量范围与红细胞输注增加(β 2.73;95% CI 0.68至4.78;P = 0.009)和血小板输注增加(β 1.74;95% CI 0.85至2.63;P < 0.001)相关。
临床怎么用
- 心脏手术体外循环后难治性出血可考虑低剂量FEIBA,但需警惕较高剂量相关的肾衰竭和输血增加风险。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bleeding during cardiac surgery may be refractory to standard interventions. Off-label use of factor eight inhibitor bypass activity (FEIBA) has been described to treat such bleeding. However, reports of safety, particularly thromboembolic outcomes, show mixed results, and reported cohorts have been small. METHODS: Adult patients undergoing cardiac surgery on cardiopulmonary bypass between July 1, 2018, and June 30, 2023, at Stanford Hospital (Stanford, California) were reviewed (n = 3,335). Patients who received FEIBA to treat postcardiopulmonary bypass bleeding were matched with those who did not by propensity scores in a 1:1 ratio using nearest neighbor matching (n = 352 per group). The primary outcome was a composite outcome of thromboembolic complications including any one of deep vein thrombosis, pulmonary embolism, unplanned coronary artery intervention, ischemic stroke, and acute limb ischemia, in the postoperative period. Secondary outcomes included renal failure, reoperation, postoperative transfusion, intensive care unit length of stay, and 30-day mortality. RESULTS: A total of 704 encounters was included in this propensity-matched analysis. The mean dose of FEIBA administered was 7.3 ± 5.5 U/kg. In propensity-matched multivariate logistic regression models, there was no statistically significant difference in odds ratios for thromboembolic outcomes, intensive care unit length of stay, or mortality. Patients who received more than 750 U FEIBA had an increased odds ratio for acute renal failure (odds ratio, 4.14; 95% CI, 1.61 to 10.36; P < 0.001). In multivariate linear regression, patients receiving FEIBA were transfused more plasma and cryoprecipitate postoperatively. However, only the dose range of 501 to 750 U was associated with an increase in transfusion of erythrocytes (β, 2.73; 95% CI, 0.68 to 4.78; P = 0.009) and platelets (β, 1.74; 95% CI, 0.85 to 2.63; P < 0.001). CONCLUSIONS: Low-dose FEIBA administration during cardiac surgery does not increase risk of thromboembolic events, intensive care unit length of stay, or mortality in a propensity-matched cohort. Higher doses were associated with increased acute renal failure and postoperative transfusion. Further studies are required to establish the efficacy of activated factor concentrates to treat refractory bleeding during cardiac surgery.
引用
- Nicholas JA, Harrison N, Chakraborty D, et al. Factor Eight Inhibitor Bypass Activity Use in Cardiac Surgery: A Propensity-matched Analysis of Safety Outcomes. Anesthesiology. 2024. PMID: 39186670. doi:10.1097/ALN.0000000000005208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。